MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597061 | Name: Ethambutol, (R,R)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ethambutol, (R,R)- is a medication primarily used to treat tuberculosis. It is usually given in combination with other tuberculosis medications, such as isoniazid, rifampicin and pyrazinamide. It may also be used to treat Mycobacterium avium complex, and Mycobacterium kansasii.

Chemical Structure

Ethambutol, (R,R)-
Ethambutol, (R,R)-
CAS#10054-05-4 (RR free base)

Theoretical Analysis

MedKoo Cat#: 597061

Name: Ethambutol, (R,R)-

CAS#: 10054-05-4 (RR free base)

Chemical Formula: C10H24N2O2

Exact Mass: 204.1838

Molecular Weight: 204.31

Elemental Analysis: C, 58.79; H, 11.84; N, 13.71; O, 15.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
74-55-5 (SS free base) 1070-11-7 (SS 2HCl) 10054-05-4 (RR free base)
Synonym
Ethambutol, (R,R)-; L-Ethambutol; (-)-Ethambutol; (R,R)-ethambutol;
IUPAC/Chemical Name
(2R)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol
InChi Key
AEUTYOVWOVBAKS-NXEZZACHSA-N
InChi Code
InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m1/s1
SMILES Code
CC[C@@H](NCCN[C@H](CC)CO)CO
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 204.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Srivastava S, Gumbo T. Clofazimine for the treatment of Mycobacterium kansasii. Antimicrob Agents Chemother. 2018 May 29. pii: AAC.00248-18. doi: 10.1128/AAC.00248-18. [Epub ahead of print] PubMed PMID: 29844047. 2: Vaghela JH, Nimbark V, Barvaliya M, Mehta H, Chavada B. Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report. Drug Saf Case Rep. 2018 May 21;5(1):23. doi: 10.1007/s40800-018-0086-z. PubMed PMID: 29785553; PubMed Central PMCID: PMC5962523. 3: Lee JY, Han J, Seo JG, Park KA, Oh SY. Diagnostic value of ganglion cell-inner plexiform layer for early detection of ethambutol-induced optic neuropathy. Br J Ophthalmol. 2018 Apr 26. pii: bjophthalmol-2018-312063. doi: 10.1136/bjophthalmol-2018-312063. [Epub ahead of print] PubMed PMID: 29699978. 4: Rezaei F, Haeili M, Fooladi AI, Feizabadi MM. High Resolution Melting Curve Analysis for Rapid Detection of Streptomycin and Ethambutol Resistance in Mycobacterium tuberculosis. Maedica (Buchar). 2017 Dec;12(4):246-257. PubMed PMID: 29610587; PubMed Central PMCID: PMC5879581. 5: Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018 Apr;6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X. Erratum in: Lancet Respir Med. 2018 Apr 18;:. PubMed PMID: 29595509. 6: Rahgozar N, Bakhshi Khaniki G, Sardari S. Evaluation of Antimycobacterial and Synergistic Activity of Plants Selected Based on Cheminformatic Parameters. Iran Biomed J. 2018 Mar 7. [Epub ahead of print] PubMed PMID: 29510602. 7: Battini S, Mannava MKC, Nangia A. Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal. J Pharm Sci. 2018 Jun;107(6):1667-1679. doi: 10.1016/j.xphs.2018.02.014. Epub 2018 Feb 17. PubMed PMID: 29462633. 8: Sieniawska E, Sawicki R, Swatko-Ossor M, Napiorkowska A, Przekora A, Ginalska G, Augustynowicz-Kopec E. The Effect of Combining Natural Terpenes and Antituberculous Agents against Reference and Clinical Mycobacterium tuberculosis Strains. Molecules. 2018 Jan 15;23(1). pii: E176. doi: 10.3390/molecules23010176. PubMed PMID: 29342972. 9: Patel N, Jagannath K, Vora A, Patel M, Patel A. A Randomized, Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Tolerability of Risorine with Conventional Rifampicin in the Treatment of Newly Diagnosed Pulmonary Tuberculosis Patients. J Assoc Physicians India. 2017 Sep;65(9):48-54. PubMed PMID: 29313577. 10: An H, Wang Z, Chen H, Wang T, Wang X, Liu L, Liu X, Xu J, He L, Zhang K, Zhang H, Liu X. Clinical efficacy of short-course chemotherapy combined with topical injection therapy in treatment of superficial lymph node tuberculosis. Oncotarget. 2017 Nov 18;8(66):109889-109893. doi: 10.18632/oncotarget.22492. eCollection 2017 Dec 15. PubMed PMID: 29299116; PubMed Central PMCID: PMC5746351. 11: Maningi NE, Malinga LA, Antiabong JF, Lekalakala RM, Mbelle NM. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa. BMC Infect Dis. 2017 Dec 28;17(1):795. doi: 10.1186/s12879-017-2898-3. PubMed PMID: 29282012; PubMed Central PMCID: PMC5745758. 12: Lee YR, Tien NI, Lin CL, Shen HY, Bau DT, Lim YP. Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-Based Case-Control Study. In Vivo. 2018 Jan-Feb;32(1):47-54. PubMed PMID: 29275298; PubMed Central PMCID: PMC5892646. 13: Kim S, Lee H, Park HY, Jeon K, Huh HJ, Lee NY, Jeong BH. Outcomes of pulmonary tuberculosis in patients with discordant phenotypic isoniazid resistance testing. Respir Med. 2017 Dec;133:6-11. doi: 10.1016/j.rmed.2017.11.004. Epub 2017 Nov 8. PubMed PMID: 29173450. 14: Chatterjee A, Nilgiriwala K, Saranath D, Rodrigues C, Mistry N. Whole genome sequencing of clinical strains of Mycobacterium tuberculosis from Mumbai, India: A potential tool for determining drug-resistance and strain lineage. Tuberculosis (Edinb). 2017 Dec;107:63-72. doi: 10.1016/j.tube.2017.08.002. Epub 2017 Aug 9. PubMed PMID: 29050774. 15: Reyes-Melo K, García A, Romo-Mancillas A, Garza-González E, Rivas-Galindo VM, Miranda LD, Vargas-Villarreal J, Favela-Hernández JMJ, Camacho-Corona MDR. meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity. Bioorg Med Chem. 2017 Oct 15;25(20):5247-5259. doi: 10.1016/j.bmc.2017.07.047. Epub 2017 Jul 29. PubMed PMID: 28844400. 16: Kwak M, Lee WK, Lim YJ, Lee SH, Ryoo S. Systematic review and meta-analysis of the nitrate reductase assay for drug susceptibility testing of Mycobacterium tuberculosis and the detection limits in liquid medium. J Microbiol Methods. 2017 Oct;141:1-9. doi: 10.1016/j.mimet.2017.07.001. Epub 2017 Jul 8. Review. PubMed PMID: 28694139. 17: Chen C, Wicha SG, de Knegt GJ, Ortega F, Alameda L, Sousa V, de Steenwinkel JEM, Simonsson USH. Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models. CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):787-797. doi: 10.1002/psp4.12226. Epub 2017 Oct 10. PubMed PMID: 28657202; PubMed Central PMCID: PMC5702905. 18: Gao M, Gao J, Du J, Liu Y, Zhang Y, Ma L, Mi F, Li L, Tang S; Trial Team. Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial. BMC Infect Dis. 2017 Jun 19;17(1):435. doi: 10.1186/s12879-017-2505-7. PubMed PMID: 28629333; PubMed Central PMCID: PMC5474865. 19: de Knegt GJ, Dickinson L, Pertinez H, Evangelopoulos D, McHugh TD, Bakker-Woudenberg IAJM, Davies GR, de Steenwinkel JEM. Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model. Tuberculosis (Edinb). 2017 Jul;105:113-118. doi: 10.1016/j.tube.2017.05.002. Epub 2017 May 8. PubMed PMID: 28610782. 20: da Silva JP, Silva IC, Pavan FR, Back DF, de Araujo MP. Bis(diphenylphosphino)amines-containing ruthenium cymene complexes as potential anti-Mycobacterium tuberculosis agents. J Inorg Biochem. 2017 Aug;173:134-140. doi: 10.1016/j.jinorgbio.2017.04.008. Epub 2017 Apr 9. PubMed PMID: 28521188.